Investors in 3D Systems Corporation securities from August 2024 to May 2025 may be eligible for compensation through a class action lawsuit. Deadline for lead plaintiff: August 12, 2025.
 |
| 3D Systems investors may lead a securities fraud lawsuit, potentially earning compensation. Rosen Law Firm offers expert legal representation with no upfront fees. Image: CH |
New York, USA — July 14, 2025:
Rosen Law Firm, a global leader in investor rights, is reminding purchasers of 3D Systems Corporation securities between August 13, 2024, and May 12, 2025 (the "Class Period") of the August 12, 2025 deadline to apply for lead plaintiff status in a securities fraud class action lawsuit.
If you purchased 3D Systems securities during the Class Period, you may be entitled to compensation at no upfront cost, as Rosen Law Firm works on a contingency fee arrangement. A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file a motion with the Court by August 12, 2025. The lead plaintiff will act on behalf of other investors, guiding the litigation process and ensuring the interests of the class are represented.
Rosen Law Firm encourages investors to choose legal counsel with a proven track record of success in securities class actions. Unlike many firms that simply serve as intermediaries, Rosen Law Firm has a deep commitment to directly litigating these complex cases. The firm has achieved impressive outcomes, including securing the largest-ever securities class action settlement against a Chinese company at the time. In 2019, Rosen Law Firm secured more than $438 million for investors. The firm’s founding partner, Laurence Rosen, was named a Titan of the Plaintiffs' Bar by Law360 in 2020. Rosen Law Firm has been ranked No. 1 for securities class action settlements by ISS Securities Class Action Services in 2017, and has consistently been ranked among the top firms in this area since 2013.
The lawsuit claims that during the Class Period, 3D Systems made misleading statements about its business performance. Specifically, it is alleged that the company downplayed the negative impact of weakening customer demand on its operations while overstating its resilience. In addition, 3D Systems failed to disclose that updated milestone criteria in its partnership with United Therapeutics would negatively affect the company’s Regenerative Medicine Program revenues. As a result of these misstatements, investors suffered financial losses when the truth was revealed.
It is important to note that no class has been certified at this time. This means investors must either retain counsel to be represented in the case or remain absent from the class action. Investors who are not interested in serving as lead plaintiff can still be part of the class, and their eligibility for any potential recovery is not dependent on taking that lead role.